Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-squamous Non-small Cell Lung Cancer: full-pipeline trial registry
2 of 10 indexed Non-squamous Non-small Cell Lung Cancer trials are currently recruiting.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Non-squamous Non-small Cell Lung Cancer: 10 US clinical trials tracked, 2 recruiting.
Non-squamous Non-small Cell Lung Cancer is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 2 of these trials.
Enrollment posture brief
Registry condition non-squamous-non-small-cell-lung-cancer
OPEN 2 | RECR 20% | LATE 5 | EARLY 4 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)
Non-squamous Non-small Cell Lung Cancer lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-squamous Non-small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-squamous Non-small Cell Lung Cancer is recruiting below its size-band peers.
2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Non-squamous Non-small Cell Lung Cancer research.
Hoffmann-La Roche accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-squamous Non-small Cell Lung Cancer enrolment sits around 420 participants.
Median target enrolment is 420 among the 10 trials that report a genuine target (sentinel values excluded). 3 of those (30%) plan for fewer than 100 participants.
-
Non-squamous Non-small Cell Lung Cancer research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
NCT06627647
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
NCT07005102
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Daiichi Sankyo
NCT05338970
Phase III Study of AK112 for NSCLC Patients
Summit Therapeutics
NCT06396065
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Arcus Biosciences
NCT04736173
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Georgetown University
NCT04958811
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
NCT01351415
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
Boehringer Ingelheim
NCT04750824
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Genentech
NCT01995188
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Hoffmann-La Roche
NCT01887886
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-squamous Non-small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-squamous Non-small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-squamous Non-small Cell Lung Cancer page
10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Non-squamous Non-small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Non-squamous Non-small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-squamous Non-small Cell Lung Cancer condition card totals 10 registered trials; most-linked intervention Carboplatin; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.